Context Therapeutics Cash and Cash Equivalents Drop to $54.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CNTX?
Cash and cash equivalents were $54.5M at March 31, 2026, compared to $66.0M at December 31, 2025. The company expects its cash and cash equivalents will be sufficient to fund its operations into mid-2027. "We continue to execute across our pipeline and believe we are making meaningful scientific and operational progress," said Martin Lehr, CEO of Context Therapeutics. "We remain on track to report Phase 1a interim clinical data from our lead program, CTIM-76, in June 2026. This update is expected to include preliminary safety, efficacy, and other correlative results. In addition, we continue to anticipate reporting Phase 1a clinical data from our CT-95 program in September 2026. In April, we received approval in Australia to advance the development of CT-202, marking an important milestone as we prepare to initiate a first-in-human clinical study later this year. We look forward to evaluating CT-202 in the clinic, and we believe this program further supports our strategy of advancing differentiated T cell engaging therapeutics for patients with significant unmet medical needs."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTX
Wall Street analysts forecast CNTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.380
Low
4.00
Averages
5.25
High
7.00
Current: 2.380
Low
4.00
Averages
5.25
High
7.00
About CNTX
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Context Therapeutics Reports Q1 Financials with Cash Position Update
- Cash Position: As of March 31, 2026, Context Therapeutics reported cash and cash equivalents of $54.5 million, down from $66.0 million at December 31, 2025, with expectations that this will fund operations into mid-2027, ensuring financial stability for the upcoming year.
- R&D Expense Increase: The company incurred $7.0 million in research and development expenses in Q1 2026, a 100% increase from $3.5 million in Q1 2025, indicating a strong commitment to accelerating product development to meet market demands.
- Slight Rise in G&A Costs: General and administrative expenses rose to $2.3 million in Q1 2026 from $2.1 million in Q1 2025, reflecting ongoing investments in operational management, which, while modest, underscore the company's focus on governance.
- Decline in Other Income: Other income decreased to $0.7 million in Q1 2026 from $1.0 million in Q1 2025, primarily due to lower interest income from cash and cash equivalents, which may exert some pressure on the company's overall profitability.
See More
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76
- FDA Fast Track Designation: Context Therapeutics announced that its lead asset CTIM-76 has received Fast Track Designation from the FDA, marking a significant advancement in the development of treatments for platinum-resistant ovarian cancer patients, which is expected to expedite clinical trials and market entry.
- Clinical Trial Progress: Currently, CTIM-76 is undergoing a Phase 1b trial for CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer patients, with interim data expected in June, which will provide critical clinical evidence for subsequent drug development.
- Market Potential: The FDA's Fast Track Designation allows developers to communicate frequently with regulators, ensuring smooth progress of clinical study plans, which not only helps shorten time to market but also positions the company favorably in the competitive cancer treatment market.
- Accelerated Approval Opportunities: Drugs with Fast Track Designation are likely to receive accelerated approval and priority review from the FDA, paving the way for CTIM-76's market launch and further enhancing the company's strategic position in the biopharmaceutical sector.
See More
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76
- FDA Fast Track Designation: Context Therapeutics' drug candidate CTIM-76 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant ovarian cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Progress: A Phase 1 study of CTIM-76 is currently underway, with interim data expected in June 2026, which will provide preliminary evidence of the drug's efficacy and safety, potentially influencing future development strategies.
- Positive Stock Reaction: Following the announcement, Context Therapeutics' shares rose over 3% in pre-market trading, starting from a closing price of $2.65 on Wednesday, indicating market optimism regarding the drug's prospects and potentially attracting more investor interest.
- Significant Market Potential: The target population for CTIM-76, consisting of patients with platinum-resistant ovarian cancer, is substantial, and the FDA's Fast Track designation not only accelerates the drug's path to market but also presents significant market opportunities, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
FDA Grants Fast Track Designation to CTIM-76 for Ovarian Cancer
- Fast Track Designation: Context Therapeutics' CTIM-76 has received Fast Track Designation from the FDA, aimed at treating patients with platinum-resistant ovarian cancer who have undergone all standard therapies, highlighting its potential to address unmet medical needs.
- Clinical Trial Progress: CTIM-76 is currently undergoing a Phase 1 clinical trial to evaluate its safety and efficacy in CLDN6-positive patients with advanced or metastatic ovarian, endometrial, and testicular cancers, with anti-tumor activity assessed through overall response rate and disease control rate.
- Data Release Expectations: The company plans to share interim data for CTIM-76 in June 2026, a critical milestone that could expedite the clinical development process and potentially accelerate subsequent regulatory approvals.
- Market Potential: As a CLDN6 x CD3 bispecific antibody, CTIM-76 indicates broad applicability across various solid tumors, particularly in platinum-resistant ovarian cancer patients, potentially offering new treatment options for a significant patient population.
See More
Context Therapeutics Reports Wider Losses in FY2025 and Pipeline Updates
- Financial Overview: Context Therapeutics reported a wider net loss of $36.13 million for FY2025, translating to a loss of $0.38 per share, compared to a loss of $26.73 million or $0.46 per share in 2024, indicating increased financial pressure that may affect future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $66 million in cash and cash equivalents, which is expected to fund operations into mid-2027; while this provides a buffer, accelerating clinical trial progress is essential to boost market confidence.
- Clinical Trial Progress: The dose escalation trial for CTIM-76 is expected to complete in the first half of 2026, with plans to evaluate a three-week dosing regimen in the second half, which, if successful, could offer new treatment options in ovarian, endometrial, and testicular cancers.
- Future Plans: Context plans to present interim data for CTIM-76 and CT-95 in June and September 2026, respectively, and anticipates dosing the first patient in the CT-202 trial in Q3 2026, which could represent significant clinical milestones for the company.
See More
Context Therapeutics Reports FY GAAP EPS
- Financial Performance: Context Therapeutics reported a FY GAAP EPS of -$0.38, indicating significant challenges in financial performance that may affect investor confidence.
- Cash Flow Situation: As of December 31, 2025, the company's cash and cash equivalents stood at $66.0 million, a notable decline from $94.4 million on December 31, 2024, reflecting increased liquidity pressure.
- Historical Financial Data: According to Seeking Alpha's Quant Rating, the historical financial data for Context Therapeutics suggests ongoing issues with profitability and cash flow management, potentially impacting future financing capabilities.
- Market Reaction Outlook: Given the negative earnings report and declining cash flow, the market is expected to adopt a cautious stance towards Context Therapeutics' future prospects, which may lead to stock price volatility.
See More
Context Therapeutics Reports Q1 Financials with Cash Position Update
- Cash Position: As of March 31, 2026, Context Therapeutics reported cash and cash equivalents of $54.5 million, down from $66.0 million at December 31, 2025, with expectations that this will fund operations into mid-2027, ensuring financial stability for the upcoming year.
- R&D Expense Increase: The company incurred $7.0 million in research and development expenses in Q1 2026, a 100% increase from $3.5 million in Q1 2025, indicating a strong commitment to accelerating product development to meet market demands.
- Slight Rise in G&A Costs: General and administrative expenses rose to $2.3 million in Q1 2026 from $2.1 million in Q1 2025, reflecting ongoing investments in operational management, which, while modest, underscore the company's focus on governance.
- Decline in Other Income: Other income decreased to $0.7 million in Q1 2026 from $1.0 million in Q1 2025, primarily due to lower interest income from cash and cash equivalents, which may exert some pressure on the company's overall profitability.
See More
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76
- FDA Fast Track Designation: Context Therapeutics announced that its lead asset CTIM-76 has received Fast Track Designation from the FDA, marking a significant advancement in the development of treatments for platinum-resistant ovarian cancer patients, which is expected to expedite clinical trials and market entry.
- Clinical Trial Progress: Currently, CTIM-76 is undergoing a Phase 1b trial for CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer patients, with interim data expected in June, which will provide critical clinical evidence for subsequent drug development.
- Market Potential: The FDA's Fast Track Designation allows developers to communicate frequently with regulators, ensuring smooth progress of clinical study plans, which not only helps shorten time to market but also positions the company favorably in the competitive cancer treatment market.
- Accelerated Approval Opportunities: Drugs with Fast Track Designation are likely to receive accelerated approval and priority review from the FDA, paving the way for CTIM-76's market launch and further enhancing the company's strategic position in the biopharmaceutical sector.
See More
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76
- FDA Fast Track Designation: Context Therapeutics' drug candidate CTIM-76 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant ovarian cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Progress: A Phase 1 study of CTIM-76 is currently underway, with interim data expected in June 2026, which will provide preliminary evidence of the drug's efficacy and safety, potentially influencing future development strategies.
- Positive Stock Reaction: Following the announcement, Context Therapeutics' shares rose over 3% in pre-market trading, starting from a closing price of $2.65 on Wednesday, indicating market optimism regarding the drug's prospects and potentially attracting more investor interest.
- Significant Market Potential: The target population for CTIM-76, consisting of patients with platinum-resistant ovarian cancer, is substantial, and the FDA's Fast Track designation not only accelerates the drug's path to market but also presents significant market opportunities, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
FDA Grants Fast Track Designation to CTIM-76 for Ovarian Cancer
- Fast Track Designation: Context Therapeutics' CTIM-76 has received Fast Track Designation from the FDA, aimed at treating patients with platinum-resistant ovarian cancer who have undergone all standard therapies, highlighting its potential to address unmet medical needs.
- Clinical Trial Progress: CTIM-76 is currently undergoing a Phase 1 clinical trial to evaluate its safety and efficacy in CLDN6-positive patients with advanced or metastatic ovarian, endometrial, and testicular cancers, with anti-tumor activity assessed through overall response rate and disease control rate.
- Data Release Expectations: The company plans to share interim data for CTIM-76 in June 2026, a critical milestone that could expedite the clinical development process and potentially accelerate subsequent regulatory approvals.
- Market Potential: As a CLDN6 x CD3 bispecific antibody, CTIM-76 indicates broad applicability across various solid tumors, particularly in platinum-resistant ovarian cancer patients, potentially offering new treatment options for a significant patient population.
See More
Context Therapeutics Reports Wider Losses in FY2025 and Pipeline Updates
- Financial Overview: Context Therapeutics reported a wider net loss of $36.13 million for FY2025, translating to a loss of $0.38 per share, compared to a loss of $26.73 million or $0.46 per share in 2024, indicating increased financial pressure that may affect future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $66 million in cash and cash equivalents, which is expected to fund operations into mid-2027; while this provides a buffer, accelerating clinical trial progress is essential to boost market confidence.
- Clinical Trial Progress: The dose escalation trial for CTIM-76 is expected to complete in the first half of 2026, with plans to evaluate a three-week dosing regimen in the second half, which, if successful, could offer new treatment options in ovarian, endometrial, and testicular cancers.
- Future Plans: Context plans to present interim data for CTIM-76 and CT-95 in June and September 2026, respectively, and anticipates dosing the first patient in the CT-202 trial in Q3 2026, which could represent significant clinical milestones for the company.
See More
Context Therapeutics Reports FY GAAP EPS
- Financial Performance: Context Therapeutics reported a FY GAAP EPS of -$0.38, indicating significant challenges in financial performance that may affect investor confidence.
- Cash Flow Situation: As of December 31, 2025, the company's cash and cash equivalents stood at $66.0 million, a notable decline from $94.4 million on December 31, 2024, reflecting increased liquidity pressure.
- Historical Financial Data: According to Seeking Alpha's Quant Rating, the historical financial data for Context Therapeutics suggests ongoing issues with profitability and cash flow management, potentially impacting future financing capabilities.
- Market Reaction Outlook: Given the negative earnings report and declining cash flow, the market is expected to adopt a cautious stance towards Context Therapeutics' future prospects, which may lead to stock price volatility.
See More
